<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170506033834N12</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-02-12</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Design and implementation of interventions to improve unplanned pregnancy experiences</public_title>
      <acronym></acronym>
      <scientific_title>Design and implementation of interventions to improve unplanned pregnancy experiences</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-06-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74839</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Other design features: This study is in line with the policy of having children and improving unplanned pregnancy experiences and reducing elective abortions, Randomization description: In order to assign the participants to the study groups, using the random block method, allocated according to the type of unplanned pregnancy (unwanted or untimely) It will be used with the size of blocks of 4 and 6 and with an allocation ratio of 1:1. For Allocation Concealment, the type of intervention is written on paper and inside matte envelopes on the back of the head. It will also be numbered. Then, the related envelope will be determined by a person not involved in open sampling and the type of intervention received.</study_design>
      <phase>N/A</phase>
      <hc_freetext>pregnancy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:The target population will be women aged 18 to 45 with an unplanned pregnancy who refer to Tabriz city health centers for prenatal care in 1403. In this step, sampling of mothers eligible to participate in the present study will be done using the available method, then Full explanations about the research, its goals and the method of its implementation will be given to the women. In case of desire to participate in the study, written informed consent will be obtained from the women and The participants will be provided with sufficient assurance regarding the confidentiality of the information obtained. , the violence and attachment of the mother to the fetus will be completed. In this study, pregnancy experience will be measured as the primary outcome and depression, anxiety, violence and attachment of the mother to the fetus and premature birth will be measured as secondary outcomes. In order to assign the participants to the study groups, using the random block method, allocated according to the type of unplanned pregnancy (unwanted or untimely) It will be used with the size of blocks of 4 and 6 and with an allocation ratio of 1:1. For Allocation Concealment, the type of intervention is written on paper and inside matte envelopes on the back of the head. It will also be numbered. Then the related envelope will be determined by a person not involved in open sampling and the type of intervention received. The type of intervention applied in the intervention group will be determined after reviewing the literature and qualitative study and holding an expert panel. Intervention 2: Control group: No intervention will be applied in the control group and only routine prenatal care will be given.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoumeh Paiandeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing and Midwifery, South Shariati, Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5313644351</zip>
        <telephone>+98 41 6770 3479</telephone>
        <email>m_paiande@yahoo.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Roghaiyeh Nourizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Nursing and Midwifery, South Shariati, Tabriz</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5138947977</zip>
        <telephone>+98 41 3477 0648</telephone>
        <email>nourizadehr@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women with unplanned pregnancies
Mother's age is 18-45 years
singleton pregnancy
Live fetus</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Vaginal bleeding (threat of miscarriage)
Previous history of depression according to mother's statement
Having maternal or fetal indications for termination of pregnancy
Disagreement with the wife according to mother's statement</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:The target population will be women aged 18 to 45 with an unplanned pregnancy who refer to Tabriz city health centers for prenatal care in 1403. In this step, sampling of mothers eligible to participate in the present study will be done using the available method, then Full explanations about the research, its goals and the method of its implementation will be given to the women. In case of desire to participate in the study, written informed consent will be obtained from the women and The participants will be provided with sufficient assurance regarding the confidentiality of the information obtained. , the violence and attachment of the mother to the fetus will be completed. In this study, pregnancy experience will be measured as the primary outcome and depression, anxiety, violence and attachment of the mother to the fetus and premature birth will be measured as secondary outcomes. In order to assign the participants to the study groups, using the random block method, allocated according to the type of unplanned pregnancy (unwanted or untimely) It will be used with the size of blocks of 4 and 6 and with an allocation ratio of 1:1. For Allocation Concealment, the type of intervention is written on paper and inside matte envelopes on the back of the head. It will also be numbered. Then the related envelope will be determined by a person not involved in open sampling and the type of intervention received. The type of intervention applied in the intervention group will be determined after reviewing the literature and qualitative study and holding an expert panel.</i_keyword>
      <i_keyword>Control group: No intervention will be applied in the control group and only routine prenatal care will be given.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pregnancy experiences. Timepoint: before the start of the intervention and again after the intervention in the 35th to 37th week of pregnancy with control of the baseline effect. Method of measurement: PES (Pregnancy Experience Scale) Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Mother's anxiety. Timepoint: before the start of the intervention and again after the intervention in the 35th to 37th week of pregnancy by controlling the effect of the baseline score. Method of measurement: PRAQ (Pregnancy-Related Anxiety Questionnaire).</sec_outcome>
      <sec_outcome>Depression. Timepoint: before the start of the intervention and again after the intervention in the 35th to 37th week of pregnancy by controlling the effect of the baseline score. Method of measurement: Edinburgh's Depression During Pregnancy Tool.</sec_outcome>
      <sec_outcome>Perceived maternal violence. Timepoint: before the start of the intervention and again after the intervention in the 35th to 37th week of pregnancy with control of the baseline effect. Method of measurement: 4-item tool HITS (Hurts, Insults, Threaten, Screams).</sec_outcome>
      <sec_outcome>Mother's attachment to the fetus. Timepoint: before the start of the intervention and again after the intervention in the 35th to 37th week of pregnancy with control of the baseline effect. Method of measurement: Cranley's mother-fetus attachment questionnaire.</sec_outcome>
      <sec_outcome>Preterm delivery. Timepoint: Frequency of preterm delivery with effect adjustment of baseline values. Method of measurement: Baby care card.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-01-06</approval_date>
        <contact_name>Ethics Committee of Tabriz University of Medical Sciences</contact_name>
        <contact_address>Golgasht St., Tabriz University of Medical Sciences, Faculity of Dentistry Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
